Evidence map›Paper›PMID 30700938›Full record

ReviewWorld journal of gastroenterology2019

Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management?

Salih Samo, Emad Qayed

Registry-linked trialAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06588348 (Corticosteroid Effect on Achalasia Variant Esophagogastric Junction Outflow Obstruction), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06588348 early_phase1active not recruitingnot on this mapstarted 2022, after this paper: background citation

Corticosteroid Effect on Achalasia Variant Esophagogastric Junction Outflow Obstruction

TypeinterventionalSponsorBaylor Research InstituteRan2022 to 2026Enrolled12ConditionsEsophagogastric Junction Outflow ObstructionArmsSteroid treatment, Esophageal Manometry, Survey
3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Esophageal motility disorders other than achalasia.Abdominal radiology (New York) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Mixed Esophageal Disease (MED): A New Concept.Digestive diseases and sciences · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction?Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022
    Article
  15. Observational
  16. Esophageal-Gastric Junction Outflow Obstruction: Are Clinicians Treating New Diseases or Treating New Findings from Old Diseases?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Salih SamoDepartment of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA 30322, United States.
Emad QayedDepartment of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA 30322, United States. eqayed@emory.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophagogastric junction outflow obstruction (EGJOO) is a major motility disorder based on the Chicago Classification of esophageal motility disorders. This entity involves a heterogenous group of underlying etiologies. The diagnosis is reached by performing high-resolution manometry. This reveals evidence of obstruction at the esophagogastric junction, manifested by an elevated integrated relaxation pressure (IRP) above a cutoff value (IRP threshold varies by the manometric technology and catheter used), with preserved peristalsis. Further tests like endoscopy, timed barium esophagram, and cross-sectional imaging can help further elucidate the underlying etiology and rule out mechanical causes. Treatment is tailored to the underlying cause. Similar to achalasia, treatment targeting lower esophageal sphincter disruption like pneumatic dilation, peroral endoscopic myotomy, and botulinum injection are used in patients with functional EGJOO and persistent symptoms.

Indexed as

Botulinum AntitoxinDilatationEsophageal Motility DisordersEsophageal Sphincter, LowerEsophagoscopyManometryMyotomyTreatment OutcomeBotulinum AntitoxinEsophagogastric junction outflow obstructionHigh-resolution manometry

Identifiers

PMID30700938
PMCPMC6350167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.